R&D | May 02, 2026
Thermo Fisher opens flagship US Bioprocess Design Center in Massachusetts
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
The microbiology unit generated $645 million in revenue in 2025 and sits within Thermo Fisher’s Specialty Diagnostics segment
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The agreement could rise to $900 million if key commercial milestones are met
The Danish biotech company confirmed the global study will begin in the second half of 2026
Health innovations are viewed more positively than food and agricultural technologies
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
EUDRAGIT polymers remain a cornerstone technology in oral drug delivery
Subscribe To Our Newsletter & Stay Updated
